دورية أكاديمية
أعرض في EDS

Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE).

التفاصيل البيبلوغرافية
العنوان: Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE).
المؤلفون: Mehta A; Cardiology, Dr Ashwani Mehta Clinic, New Delhi, IND., Jain P; Cardiology, Indraprastha Apollo Hospitals, New Delhi, IND., Patil R; Internal Medicine, Sevasadan Lifeline Superspecialty Hospital, Miraj, IND., Sashi Kant T; Internal Medicine, Sri Sai Heart Care Clinic, Hyderabad, Hyderabad, IND., Indurkar SA; Internal Medicine, Diabetes Clinic, Aurangabad, IND., Kota SK; Internal Medicine, Diabetes & Endocare Clinic, Berhampur, IND., Revankar S; Scientific Services, USV Private Limited, Mumbai, IND., Gupta A; Scientific Services, USV Private Limited, Mumbai, IND.
المصدر: Cureus [Cureus] 2022 Nov 14; Vol. 14 (11), pp. e31468. Date of Electronic Publication: 2022 Nov 14 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Background Rosuvastatin effectively reduces endogenous cholesterol synthesis and low-density lipoprotein (LDL) cholesterol and increases high-density lipoprotein (HDL) cholesterol. This study aimed to evaluate the clinical characteristics of patients and treatment patterns of rosuvastatin as a lipid-lowering therapy for primary and secondary prevention of cardiovascular events in Indian settings. Methods This real-world, retrospective multi-centric observational study included patients aged >18 years who received treatment with a rosuvastatin/rosuvastatin-based combination. Demographic and data about concomitant diseases and medications were recorded. Results Out of 1,816 patients, the majority were men (66.2%); the mean age was 54.1 years. The patients prescribed rosuvastatin for primary and secondary prevention of cardiovascular events were 71.9% and 28.1%, respectively. Rosuvastatin 10 mg (56.8%) was the most commonly prescribed dose. For primary prevention, 10 mg (65.0%) was the most preferred dose, and for secondary prevention, 20 mg (54.3%) was the most preferred dose. Rosuvastatin treatment significantly (pre- vs. post-treatment) reduced the levels of total cholesterol (227.2 vs. 178.4 mg/dL), triglycerides (212.6 vs. 154.4 mg/dL), and LDL cholesterol (167.0 vs. 125.6 mg/dL), and increased HDL cholesterol levels (40.7 vs. 44.3 mg/dL) (p<0.0001). A total of 1,196 patients received combination therapy with rosuvastatin (aspirin, 34.0%, and fenofibrate, 21.9%). Adverse events were reported in 0.4% of the study population (leg pain, nausea, muscle cramps/pain, bleeding, and myalgia). Conclusion This study demonstrated the clinical effectiveness and safety of moderate- to high-intensity rosuvastatin (5-40 mg) for primary and secondary prevention of cardiovascular events in the Indian population. A primary prevention strategy with statins can reduce cardiovascular events and associated morbidity and mortality.
Competing Interests: The authors have declared financial relationships, which are detailed in the next section.
(Copyright © 2022, Mehta et al.)
References: J Clin Diagn Res. 2016 Jul;10(7):OE01-5. (PMID: 27630892)
Eur Heart J. 2016 Aug 1;37(29):2315-2381. (PMID: 27222591)
Lancet Neurol. 2009 May;8(5):453-63. (PMID: 19375663)
Stroke. 2014 Jul;45(7):2160-236. (PMID: 24788967)
N Engl J Med. 2006 Aug 10;355(6):549-59. (PMID: 16899775)
Circulation. 2019 Jun 18;139(25):e1046-e1081. (PMID: 30565953)
Lancet Glob Health. 2018 Dec;6(12):e1339-e1351. (PMID: 30219317)
Lipids Health Dis. 2017 Jul 3;16(1):130. (PMID: 28673294)
Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005195. (PMID: 30917685)
J Assoc Physicians India. 2016 Mar;64(3 suppl):7-52. (PMID: 28762263)
Stroke. 2019 Dec;50(12):e344-e418. (PMID: 31662037)
N Engl J Med. 2018 Oct 18;379(16):1509-1518. (PMID: 30221597)
Indian Heart J. 2017 May - Jun;69(3):382-392. (PMID: 28648438)
Diabetes Care. 2020 Aug;43(8):1977-1978. (PMID: 32503834)
JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 1):1518-1528. (PMID: 30553686)
PLoS One. 2014 May 09;9(5):e96808. (PMID: 24817067)
J Assoc Physicians India. 2020 Jul;68(7):57-61. (PMID: 32602682)
J Assoc Physicians India. 2018 Mar;66(3):70-4. (PMID: 30341873)
N Engl J Med. 2018 Oct 18;379(16):1529-1539. (PMID: 30146931)
Am J Cardiol. 2014 May 15;113(10):1753-64. (PMID: 24792742)
J Family Med Prim Care. 2020 Aug 25;9(8):4156-4164. (PMID: 33110825)
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. (PMID: 24222016)
Eur J Prev Cardiol. 2017 Aug;24(12):1294-1296. (PMID: 28504565)
Circulation. 2019 Sep 10;140(11):e596-e646. (PMID: 30879355)
Lancet. 2009 May 30;373(9678):1849-60. (PMID: 19482214)
Clin Med Insights Cardiol. 2012;6:17-33. (PMID: 22442638)
Eur Heart J. 2020 Jan 1;41(1):111-188. (PMID: 31504418)
فهرسة مساهمة: Keywords: dose titration; dyslipidemia; high-intensity; rosuvastatin; statins
تواريخ الأحداث: Date Created: 20221216 Latest Revision: 20221221
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9748627
DOI: 10.7759/cureus.31468
PMID: 36523717
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.31468